Vaccine Policy Volatility, COVID Updates, and Measles Surveillance

Federal 2026–27 influenza, COVID-19, and RSV guidance remains unsettled while CDC, states, and professional groups issue population-specific advice. The AAP schedule diverges from the federal version, and Moderna's mFLUSIVA claims and access remain under scrutiny; unverified withdrawal claims should not be presented as established evidence. Measles exposure notices and case reporting remain actionable, but exposure alerts do not establish local transmission.